FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer
WASHINGTON, D.C. — The U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of …
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer Read More